Pliant Therapeutics Inc (Pliant Therapeutics) is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of fibrosis. The company’s pipeline products include PLN-74809, PLN-101095, PLN-101325 and PLN-1474. Its pipeline candidates treat idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), solid tumors, other muscular dystrophies and NASH-associated liver fibrosis. The company is also evaluating therapies to treat muscular dystrophy, solid tumors, and cancer. It works in partnership with Novartis AG and other institutions, universities, medical centers, physicians and researchers to develop its products. Pliant Therapeutics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
260 Littlefield Avenue, Suite 150, South San Francisco, California, 94080
Website
pliantrx.com
Telephone
1 650 4816770
No of Employees
158
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PLRX (NASD)
Revenue (2022)
$1.6M
-83.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-30.8%
(2022 vs 2021)
Market Cap*
$716.9M
Net Profit Margin (2022)
XYZ
-701.9%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| PLN-74809: Idiopathic Pulmonary Fibrosis (IPF), Primary Sclerosing Cholangitis (PSC) |
| PLN-101095: Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Pliant Therapeutics Inc | AbbVie Inc | Novartis AG | Bristol-Myers Squibb Co | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | South San Francisco | North Chicago | Basel | Princeton | Foster City |
| State/Province | California | Illinois | - | New Jersey | California |
| No. of Employees | 158 | 50,000 | 76,057 | 34,100 | 18,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Hoyoung Huh, M.D., Ph.D. | Chairman | Executive Board | 2017 | 53 |
| Bernard Coulie, M.D., Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2016 | 57 |
| Keith Cummings, M.D., MBA | Chief Financial Officer | Senior Management | 2018 | 46 |
| Eric Lefebvre, M.D. | Chief Medical Officer | Senior Management | 2018 | 59 |
| Scott Turner, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer